SXTP60 DEGREES PHARMACEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of 60 DEGREES PHARMACEUTICALS, INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SXTPThis | $3M#6 | — | 1.3x#5 | 3.3x#2 | 65.5%#1 | 7.3%#3 | -771.6%#2 | -281.7%#4 | -163.8%#3 | 6#1 | — | — |
| SBFM | $4M#1 | 0.2x#2 | 0.1x#1 | 0.1x#1 | 4.1%#2 | -16.4%#4 | -17.2%#1 | -21.7%#1 | -63.1%#1 | — | -93.1%#4 | — |
| CVKD | $4M#2 | — | 0.9x#4 | — | — | -24.3%#5 | — | -323.5%#5 | -585.1%#4 | — | -91.9%#2 | — |
| HCWB | $4M#3 | 0.1x#1 | 0.5x#3 | 67.7x#3 | -97.9%#4 | 73.5%#1 | -24270.7%#3 | -107.2%#2 | -99.4%#2 | 3#2 | -92.1%#3 | — |
| BIVIW | $4M#4 | — | 0.4x#2 | — | — | -25.8%#6 | — | -214.9%#3 | -1671.2%#5 | — | -7.7%#1 | — |
| TCRT | $3M#5 | — | 5.3x#6 | 685.9x#5 | -50.0%#3 | 10.8%#2 | -84500.0%#5 | -640.5%#6 | — | — | — | — |
| JUNS | $2M#7 | — | — | 112.9x#4 | — | -254.4%#7 | -40873.2%#4 | — | — | — | -97.3%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice